News & Events about Blueprint Medicines Corp.
Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual...
Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) has received a consensus recommendation of Moderate Buy from the nineteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given...
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire CAMBRIDGE, Mass., Jan. 6, 2023 CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the...
Shares of Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) have been assigned a consensus rating of Hold from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold ...
Ticker Report
2 months ago
Shares of Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) have been assigned a consensus rating of Hold from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ...